Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
99.49
-2.25 (-2.21%)
At close: Jun 27, 2025, 4:00 PM
99.42
-0.07 (-0.08%)
After-hours: Jun 27, 2025, 7:45 PM EDT
Insmed Revenue
Insmed had revenue of $92.82M in the quarter ending March 31, 2025, with 22.94% growth. This brings the company's revenue in the last twelve months to $381.03M, up 20.77% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$381.03M
Revenue Growth
+20.77%
P/S Ratio
44.93
Revenue / Employee
$299,788
Employees
1,271
Market Cap
18.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INSM News
- 12 days ago - Is Insmed Stock Overvalued After The 45% Jump? - Forbes
- 16 days ago - Insmed Announces Pricing of $750 Million Public Offering of Common Stock - PRNewsWire
- 16 days ago - Insmed Announces Proposed $650 Million Public Offering of Common Stock - PRNewsWire
- 16 days ago - Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast - Benzinga
- 17 days ago - Insmed: Company Presses On With Further POC PAH Treatment Data - Seeking Alpha
- 18 days ago - Insmed's blood pressure drug meets main goal in mid-stage trial - Reuters
- 18 days ago - Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension - PRNewsWire
- 23 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire